Compositions and methods for treatment of severe acute...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/395 (2006.01) A61K 31/7088 (2006.01) A61K 38/19 (2006.01) A61P 31/14 (2006.01)

Patent

CA 2526431

Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.

La présente invention a trait à des compositions et procédés pour le traitement du syndrome respiratoire aigu sévère (SRAS). L'invention a trait à des inhibiteurs de cytokines inflammatoires associées au SRAS destinés à être utilisés dans de traitement du SRAS, y compris l infection par le coronavirus lié au SRAS (SRAS-CoV). L'invention a également trait à des inhibiteurs du facteur de nécrose tumorale, ainsi que l'utilisation desdits inhibiteurs pour le traitement du SRAS, y compris le SRAS-CoV. L'invention a trait en outre à des procédés d'identification et de criblage pour lesdits inhibiteurs.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Compositions and methods for treatment of severe acute... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for treatment of severe acute..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of severe acute... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1651810

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.